（文章来源：证券日报） 证券日报网讯 1月26日，信邦制药在互动平台回答投资者提问时表示，截至2024年度，在中成药方面， 公司拥有11个国家基药目录品种，23个国家医保目录品种，主要品种益心舒胶囊、脉血康胶囊、关节克 痹丸（独家品种）、银杏叶片、六味安消胶囊、贞芪扶正胶囊均在国家医保目录中。 ...

Core Viewpoint - The article discusses the medicinal properties and applications of the fruit of the Ligustrum lucidum, commonly known as Nuozhenzi, highlighting its benefits for liver and kidney health, as well as its use in various traditional Chinese medicine formulations [1][2]. Group 1: Medicinal Properties - Nuozhenzi is known for its sweet and bitter taste, cool nature, and its ability to nourish the liver and kidneys, clear heat, improve vision, and darken hair [1]. - Modern pharmacological studies indicate that Nuozhenzi has anti-inflammatory, diuretic, laxative, lipid-lowering, and liver-protective effects, enhancing immune function [1]. Group 2: Applications in Traditional Medicine - Various formulations containing Nuozhenzi include: - Nuozhenzi syrup for treating kidney and liver deficiencies leading to symptoms like weakness and premature graying [2]. - Zhenqi Fuzheng capsules for chronic illness recovery and support during cancer treatments [2]. - Jingwu granules for insomnia and hair loss [2]. - Dongqing supplement for kidney deficiency and related symptoms [2]. - Wufawan for treating youth-related graying [2]. - Compound Siwei Nuozhenzi capsules for menopausal syndrome and premenstrual tension [2]. Group 3: Recipes and Preparation - Nuozhenzi porridge: Made with 10 grams of Nuozhenzi and 100 grams of rice, cooked together [3][4]. - Nuozhenzi and goji berry soup: Includes 30 grams of Nuozhenzi, 15 grams of goji berries, and 250 grams of lean pork, simmered for 2-3 hours [7][8]. - Nuozhenzi tea: A blend of Nuozhenzi, goji berries, and other herbs, steeped in hot water [9][10]. - Nuozhenzi wine: Prepared by soaking 120 grams of chopped Nuozhenzi with sweeteners in alcohol for about 30 days [13][14].

Core Viewpoint - Gansu Dingxi City is transforming its agricultural economy by implementing a dual approach of strengthening traditional industries and fostering emerging sectors, leading to significant industrial growth and investment attraction. Group 1: Industrial Growth and Investment - Dingxi has increased its number of industrial enterprises to 295, up by 177 since 2020, with an average annual industrial value-added growth of 16% during the 14th Five-Year Plan period [1] - The city has seen an increase in external investment from 206.86 billion yuan in 2020 to 730.82 billion yuan in 2024, with an annual growth rate of 37.1% [3] - The establishment of 12 specialized teams for industrial chain investment has contributed to the influx of major companies like Guangyao Group and Sany Heavy Energy [3] Group 2: Policy Support and Financial Investment - Dingxi High-strength Fasteners Co., Ltd. has received over 10 million yuan in various policy funds since the 14th Five-Year Plan, which has been invested in R&D and modernization [2] - The city has implemented policies such as stable employment subsidies and technology transformation rewards to support local enterprises [2] Group 3: Agricultural Transformation - The agricultural sector is being restructured through industrialization and clustering, with companies like Gansu Fuzheng Pharmaceutical Co., Ltd. establishing standardized planting bases and connecting with thousands of local farmers [4][5] - The potato industry has seen significant growth, with companies like Gansu Blue Sky Potato Industry Development Co., Ltd. creating a closed-loop ecosystem that includes supply chain finance and product diversification [6][7] Group 4: New Energy and Digital Transformation - Gansu Dongxing Jiaxin New Materials Co., Ltd. is focusing on a green and integrated aluminum industry chain, achieving significant energy savings and CO2 reduction [8] - The integration of digital technology in traditional industries has led to a 25% increase in production efficiency, with 100% of large-scale enterprises participating in digital transformation [8] Group 5: Future Development Strategy - Dingxi aims to establish itself as a distinctive industrial hub in the Longzhong region, focusing on resilience, innovation, structural optimization, and low-carbon transformation as part of its development strategy [9]

Core Viewpoint - Xinfang Pharmaceutical is embroiled in a bribery scandal, leading to its prosecution by the procuratorate, which has caused a significant drop in its stock price [1][4]. Group 1: Company Overview - Xinfang Pharmaceutical is a comprehensive healthcare group covering medical services, pharmaceutical distribution, and manufacturing, listed on the A-share market in 2010 [2]. - The company has been experiencing declining operational performance, with continuous revenue and profit decreases in 2024 and the first three quarters of 2025 [3][12]. Group 2: Legal Issues - The company and its subsidiary, Guizhou Keke Pharmaceutical, are both implicated in a unit bribery case, with the procuratorate receiving materials for prosecution [1][4]. - The specific details of the bribery allegations have not been disclosed, and the company is awaiting further legal proceedings [5][6]. Group 3: Financial Performance - In 2023, Guizhou Keke Pharmaceutical reported revenues of 2.278 billion yuan and a net profit of 94.5 million yuan, contributing significantly to Xinfang's overall financials [6]. - Xinfang's revenue and net profit have shown a downward trend, with 2024 figures indicating a 6.63% and 64.70% decline, respectively [12]. - The company's R&D investment remains low, with only 4.29 million yuan spent in the first three quarters of 2025, compared to 196 million yuan in sales expenses [3][12].